The local medical community is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in scientific trials for managing obesity. This https://ezmarkbookmarks.com/story21890366/retatrutide-australia-australia-a-potential-hope-for-obesity-treatment